The aim of this study is to investigate whether the benefit of abciximab in patients with non-ST-segment elevation acute coronary syndromes ( NSTE-ACSs ) undergoing percutaneous coronary intervention ( PCI ) after pre-treatment with 600 mg clopidogrel is sustained at 1 year .
